Restoring p53 Function in Sarcomas Using MDM2 Inhibitors

MDM2 is an E3 ubiquitin ligase and the principal negative regulator of the tumor suppressor gene TP53, maintaining cellular homeostasis through a tightly controlled feedback loop in which p53 transcriptionally activates MDM2, and MDM2, in turn, ubiquitinates p53 for degradation.In several sarcomas, particularly well-differentiated and dedifferentiated liposarcomas, MDM2 amplification at chromosome 12q15 suppresses p53 activity despite retention of a wild-type TP53 gene.This makes the p53-binding pocket of MDM2 an attractive therapeutic target in these tumors.Over the past two decades, eight small-molecule MDM2 inhibitors have entered clinical trials, including RG7112, idasanutlin, SAR405838, HDM201, APG-115, navtemadlin, milademetan, and BI-907828, with seven advancing to later-stage evaluation.Although none have yet received regulatory approval, early-phase studies have demonstrated pharmacodynamic proof of concept, evidenced by p53 stabilization, induction of downstream targets such as p21, and tumor growth arrest in MDM2-amplified models and patients.This study compares the effectiveness of these inhibitors in the context of MDM2-amplified sarcomas, where excessive MDM2 expression suppresses wild-type TP53 activity.Pharmacologic blockade of the p53-MDM2 interaction can release p53 from inhibition, thereby restoring its tumor-suppressive functions and inducing cell-cycle arrest or apoptosis in cancer cells.